In silico study in the drug design for essential tremor treatment

Vol. 1, 2019 - 109205
Poster only
Favorite this paper
How to cite this paper?
Abstract

Essential tremor (ET) is the most common movement disorder and characterized by producing involuntary
oscillatory and rhythmic movements when the patient performs some actions and may impair the quality of
his life1. The main pharmacotherapy for ET is the use of propranolol, in which it is a non-selective β-
adrenergic receptor antagonist3,5. Some adverse effects are related about the use of this medication, the
main ones acting on the Central Nervous System, such as fatigue and may even reach depression4,5. Thus,
with the use of databases and computer softwares, new proposals were created and tested to confirm their
effectiveness, through the ADME/Tox tests, to verify potential activity and interaction with the therapeutic
target2. In all, three proposals with better results to the drug already commercially distributed. Therefore,
further tests and studies should be performed to verify the actual effect of these for the treatment of essential
tremor.

Track
  • 1. Strategies in Drug Design
Keywords
movement desorder
propranolol
Beta adrenergic receptor